BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 23539448)

  • 1. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
    Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
    Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
    Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L
    Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioneer of prostate cancer: past, present and the future of FOXA1.
    Teng M; Zhou S; Cai C; Lupien M; He HH
    Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
    Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
    Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.
    Imamura Y; Sakamoto S; Endo T; Utsumi T; Fuse M; Suyama T; Kawamura K; Imamoto T; Yano K; Uzawa K; Nihei N; Suzuki H; Mizokami A; Ueda T; Seki N; Tanzawa H; Ichikawa T
    PLoS One; 2012; 7(8):e42456. PubMed ID: 22879989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
    Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML
    Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
    Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
    Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
    Jin HJ; Zhao JC; Wu L; Kim J; Yu J
    Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression.
    Xu B; Song B; Lu X; Kim J; Hu M; Zhao JC; Yu J
    Cell Res; 2019 Sep; 29(9):773-775. PubMed ID: 31324884
    [No Abstract]   [Full Text] [Related]  

  • 10. Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.
    Stelloo S; Nevedomskaya E; Kim Y; Hoekman L; Bleijerveld OB; Mirza T; Wessels LFA; van Weerden WM; Altelaar AFM; Bergman AM; Zwart W
    Oncogene; 2018 Jan; 37(3):313-322. PubMed ID: 28925401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.
    Robinson JL; Hickey TE; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Neal DE; Tilley WD; Carroll JS
    Oncogene; 2014 Dec; 33(50):5666-74. PubMed ID: 24292680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
    Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
    Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression.
    Song B; Park SH; Zhao JC; Fong KW; Li S; Lee Y; Yang YA; Sridhar S; Lu X; Abdulkadir SA; Vessella RL; Morrissey C; Kuzel TM; Catalona W; Yang X; Yu J
    J Clin Invest; 2019 Feb; 129(2):569-582. PubMed ID: 30511964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5.
    Lin CY; Jan YJ; Kuo LK; Wang BJ; Huo C; Jiang SS; Chen SC; Kuo YY; Chang CR; Chuu CP
    Cancer Sci; 2018 Nov; 109(11):3564-3574. PubMed ID: 30142696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
    Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
    BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.
    Goel S; Bhatia V; Kundu S; Biswas T; Carskadon S; Gupta N; Asim M; Morrissey C; Palanisamy N; Ateeq B
    Nat Commun; 2021 Sep; 12(1):5325. PubMed ID: 34493733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forkhead domain mutations in FOXA1 drive prostate cancer progression.
    Gao S; Chen S; Han D; Barrett D; Han W; Ahmed M; Patalano S; Macoska JA; He HH; Cai C
    Cell Res; 2019 Sep; 29(9):770-772. PubMed ID: 31324883
    [No Abstract]   [Full Text] [Related]  

  • 19. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
    Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
    EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.